MedPath

Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU )

Not Applicable
Completed
Conditions
HIV Infections
Exposure During Pregnancy
Neurophysiologic Abnormality
Executive Dysfunction
Interventions
Diagnostic Test: BRIEF SCORE AT INCLUSION
Registration Number
NCT04108728
Lead Sponsor
Nantes University Hospital
Brief Summary

Main objective: to evaluate the executive functioning of the HIV exposed uninfected children (HEU) versus children from the same socio-economic and cultural environment, not infected or affected by HIV.

Secondary objective (s): to evaluate Intellectual Quotient, Child development, Behavior, Language and investigate link between executive functioning disorders, exposure to ARVs, HIV and family environment.

Detailed Description

The objective of the study is the exploration of executive functions (EF) and screening for neurodevelopment and learning disorders in children born to HIV-infected mothers, exposed to the virus and to antiretrovirals (ARVs).

The evaluation of the executive functioning will be done by the score obtained at the preschool BRIEF for patients and control group issued from questionnaires filled by the mothers of the cases and the mothers of the controls, with matching on age, sex, level of parental education and socio-economic and cultural environment.

Within the group of exposed children, factors associated with executive dysfunction including HIV infection, antiretroviral exposure, maternal socio-demographic data, sociocultural and environmental level will be investigated.

Evolution of the scores between J0, M12 and M24 will be compared within the group of exposed children.

Compared with a control group, the child's intelligence quotient, overall development, behavior and language will be compared at each follow-up time (D0, M12 and M24).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • experimental:

    • HIV-positive children born to mothers living with HIV antiretrovirals during pregnancy and in the neonatal period, aged 3 years +/- 3 months on the date of inclusion.
    • Parents mastering the French.
  • control:

    • children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, no infected or affected by HIV.
    • Parents mastering French.
Exclusion Criteria
  • great prematurity (28-32 weeks)
  • genetic anomaly

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HIV exposed children during pregnancyBRIEF SCORE AT INCLUSIONchildren born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language
control childrenBRIEF SCORE AT INCLUSIONchildren, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.
Primary Outcome Measures
NameTimeMethod
evaluate the executive function of children HEUinclusion

Behaviour rating inventary of executive function (BRIEF) preschool version score

Secondary Outcome Measures
NameTimeMethod
behaviourat INCLUSION, 12 months after inclusion, 24 months after inclusion

Strengths and Difficulties Questionnaire score

functional developmentat INCLUSION, 12 months after inclusion, 24 months after inclusion

age and stage questionnaires score

Intellectual quotientat INCLUSION, 12 months after inclusion, 24 months after inclusion

Wechsler tests score

language12 months after inclusion,

language dysfunction scale score

Trial Locations

Locations (3)

Chu Angers

🇫🇷

Angers, France

Chd Vendee

🇫🇷

La Roche-sur-Yon, France

Chu de Nantes

🇫🇷

Nantes, France

© Copyright 2025. All Rights Reserved by MedPath